-
"By further accelerating the globalization of our research capabilities, we aim to develop innovative drug candidates that create life-changing value."
Global Research Head
Yoshifumi Torii, Ph.D.
-
"While adapting to the ever-changing external environment, we will concentrate resources on our key focus areas and advance clinical development from multiple perspectives."
Global Development Head
Ernesto Aycardi
R&D Structure
-
GRO - Global Research Organization
Our GRO serves as Kyowa Kirin’s global research organization, with bases in Japan, the United States, and the United Kingdom collaborating on advancing innovative drug discovery.
Leveraging a flat organizational structure and specialized expertise, GRO aims to develop life-changing drug candidates through agile research tailored to each disease area.
-
GDO - Global Development Organization
Our GDO is a global development organization that integrally advances projects beyond the non-clinical stage. Working seamlessly with GRO, we pursue the realization of patient-centered, value-added pharmaceuticals by prioritizing diversity, speed, and quality.
Global Integration of
R&D Organization
Kyowa Kirin is engaged in global drug discovery research to develop innovative pharmaceuticals at our Tokyo and Fuji Research Parks in Japan, as well as our La Jolla Institute in the USA, and Hammersmith Laboratory in the UK. In the area of clinical development, our three bases—Tokyo headquarters, USA, and UK—collaborate to accelerate new drug development across the Asia-Pacific (including Japan), North America, and the EMEA region (Europe, the Middle East, and Africa). Through a cross-regional framework that shares expertise, we aim to deliver life-changing value to patients worldwide as quickly as possible.
Click below for a list of Kyowa Kirin Group company locations.
